{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:31:02Z","timestamp":1770496262124,"version":"3.49.0"},"reference-count":92,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2025,4,13]]},"DOI":"10.1080\/14656566.2025.2481205","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T03:22:06Z","timestamp":1743132126000},"page":"707-717","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Management of Parkinson\u2019s disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching"],"prefix":"10.1080","volume":"26","author":[{"given":"Stuart H.","family":"Isaacson","sequence":"first","affiliation":[{"name":"Parkinson\u2019s Disease and Movement Disorders Center of Boca Raton","place":["Boca Raton, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Nasrallah","sequence":"additional","affiliation":[{"name":"University of Cincinnati","place":["Cincinnati, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Alva","sequence":"additional","affiliation":[{"name":"University of California","place":["Riverside, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kremens","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University","place":["Philadelphia, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Stahl","sequence":"additional","affiliation":[{"name":"University of California","place":["San Diego, USA"]},{"name":"Neuroscience Education Institute","place":["Carlsbad, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-150685"},{"key":"e_1_3_5_4_1","unstructured":"FDA clears first drug for Parkinson\u2019s dyskinesia [internet]. WebMD LLC; c1994\u20132024 [cited 2024 Feb 20]. Available from: https:\/\/www.medscape.com\/viewarticle\/884697?form=fpf"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27131"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2017.91"},{"key":"e_1_3_5_7_1","unstructured":"FDA clears droxidopa for neurogenic orthostatic hypotension [internet]. c1994\u20132024 [cited 2024 Feb 20]. Available from: https:\/\/www.medscape.com\/viewarticle\/820786?form=fpf"},{"key":"e_1_3_5_8_1","unstructured":"US Food and Drug Administration. [updated FDA approves first drug to treat hallucinations and delusions associated with Parkinson\u2019s disease [internet]. 2019 Mar 1 [cited 2024 Feb 20]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-hallucinations-and-delusions-associated-parkinsons-disease"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62106-6"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.06.026"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852918001359"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852918001013"},{"key":"e_1_3_5_13_1","volume-title":"First-generation versus second-generation antipsychotics in adults: comparative effectiveness","author":"Abou-Setta AM","year":"2012","unstructured":"Abou-Setta AM, Mousavi SS, Spooner C, et al. First-generation versus second-generation antipsychotics in adults: comparative effectiveness. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012."},{"issue":"4","key":"e_1_3_5_14_1","first-page":"5","article-title":"An overview of side effects caused by typical antipsychotics","volume":"61","author":"Arana GW","year":"2000","unstructured":"Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry. 2000;61(4):5\u201313.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"e_1_3_5_15_1","first-page":"737","article-title":"Le syndrome extrapyramidal et dienc\u00e9phalique au cours des traitements aulargactil et au aerpasil [Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments]","volume":"112","author":"Steck H","year":"1954","unstructured":"Steck H. Le syndrome extrapyramidal et dienc\u00e9phalique au cours des traitements aulargactil et au aerpasil [Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments]. Ann Med Psychol (Paris). 1954;112(2 5):737\u2013744. French.","journal-title":"Ann Med Psychol (Paris)"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10374"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1017\/9781108975292"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2069240"},{"issue":"5","key":"e_1_3_5_19_1","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"Muench J","year":"2010","unstructured":"Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617\u2013622.","journal-title":"Am Fam Physician"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-022-00942-1"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216010-00003"},{"issue":"2","key":"e_1_3_5_22_1","first-page":"3","article-title":"Atypical antipsychotics: sleep, sedation, and efficacy","volume":"6","author":"Miller DD","year":"2004","unstructured":"Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004;6(suppl 2):3\u20137.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.04.003"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2022.01.022"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-225060"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28722"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23083"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852916000407"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852916000602"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.35"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2022.09.006"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp166"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.22577"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1192\/bja.2019.79"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21382"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2020.09.002"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.5.595"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00707-7"},{"issue":"5","key":"e_1_3_5_39_1","first-page":"289","article-title":"Poor visual discrimination and visual hallucinations in Parkinson\u2019s disease","volume":"21","author":"Diederich NJ","year":"1998","unstructured":"Diederich NJ, Goetz CG, Raman R, et al. Poor visual discrimination and visual hallucinations in Parkinson\u2019s disease. Clin Neuropharmacol. 1998;21(5):289\u2013295.","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000148479.10865.FE"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00388-y"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2017.11.262"},{"key":"e_1_3_5_43_1","unstructured":"Seroquel\u00ae. Prescribing information [internet]. AstraZeneca; c2013 [updated 2013 Oct; cited 2023 Jul 11]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020639s061lbl.pdf"},{"key":"e_1_3_5_44_1","unstructured":"Nuplazid\u00ae. Prescribing information [internet]. Acadia Pharmaceuticals Inc.; c2023 [updated 2023 Sep; cited 2023 Jul 11]. Available from: https:\/\/www.nuplazidhcp.com\/pdf\/nuplazid-prescribing-information.pdf"},{"key":"e_1_3_5_45_1","unstructured":"Clozaril\u00ae. Prescribing information [internet]. HLS Therapeutics (USA) Inc.; c2020 [updated 2020 Feb; cited 2023 Jul 11]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/019758s095lbl.pdf"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27602"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.04.012"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.18080180"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18372"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-021-00284-1"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13652"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2152600"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0114"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21090876"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.6.785"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01260-6"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.029868"},{"issue":"1","key":"e_1_3_5_59_1","first-page":"46","article-title":"Pimavanserin in the treatment of Parkinson\u2019s disease psychosis: meta-analysis and meta-regression of randomized clinical trials","volume":"19","author":"Mansuri Z","year":"2022","unstructured":"Mansuri Z, Reddy A, Vadukapuram R, et al. Pimavanserin in the treatment of Parkinson\u2019s disease psychosis: meta-analysis and meta-regression of randomized clinical trials. Innov Clin Neurosci. 2022;19(1\u20133):46\u201351.","journal-title":"Innov Clin Neurosci"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/08919887231154933"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.076487"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401003"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000260060.60870.89"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20474"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21116"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S5335"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.3109\/00207450903222758"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.3_Part_1.544"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2024.02.008"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12266"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02257654"},{"key":"e_1_3_5_72_1","unstructured":"Zaponex 25 mg orodispersible tablets summary of product characteristics [internet]. Datapharm Ltd; [updated 2020 Jun; cited 2025 Feb 25]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/10119\/smpc"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13582"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1017\/9781108553575"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0311-1"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1017\/S204579602200066X"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.139"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02265-x"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02075-8"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.0031"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012601"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2220597"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21010"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2010.11.009"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246121"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200113"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-202058"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130302"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0943-4"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.5.713"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22132"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.9.975"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01084-1"},{"key":"e_1_3_5_94_1","unstructured":"McCarthy D Zajac D Thomas A. Quick Reference Document for Changing Antipsychotic Regimens for Treatment of Parkinson\u2019s Disease Psychosis (PDP). Published March 2024. ASCP.com. Alexandria Virginia. https:\/\/cdn.ymaws.com\/www.ascp.com\/resource\/resmgr\/docs\/prc\/PDP_Charts_V2.pdf"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2025.2481205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T04:08:16Z","timestamp":1744603696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2025.2481205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,4,13]]}},"alternative-id":["10.1080\/14656566.2025.2481205"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2025.2481205","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}